-- 根據《日經新聞》週二報道，日本經濟產業省將提供40億日圓（約2,520萬美元）的補貼，支持莫三比克和加納開展一項大規模海洋生物燃料試點計畫。 報告稱，這筆資金旨在支付計畫啟動成本，直到計畫獲利，其雙重目標是在實現能源來源多元化的同時，幫助改善環境並惠及當地農民。 該計畫由總部位於東京的日本生質燃料公司牽頭，將種植麻風樹。報導稱，這種生命力頑強的植物能夠在貧瘠的土壤中生長，並能產出富含油脂的種子，而且不會像玉米或其他生物燃料作物那樣對糧食供應造成壓力。 報導稱，燃料生產設施將在兩國建設，並僱用當地工人負責從種植到生產的各個環節。 報導還補充說，最終生產的生物燃料預計將為日本國內貨船、開往非洲的貨船以及以新加坡為基地的商船提供動力，從而解決多重挑戰。 （市場動態新聞來自與全球市場專業人士的對話。這些資訊據信來自可靠來源，但可能包含傳聞和推測。準確性無法保證。）
Related Articles
Research
Research Alert: CFRA Initiates Coverage On Riocan Real Estate Investment Trust With A Hold View
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We initiate coverage on shares of REI.UN with a 12-month target price of $22, applying a forward P/FFO multiple of 13.1x to our 2026 FFO estimate, a premium to the three-year forward average of 10.4x. We start our 2026 FFO per share estimate at $1.68 and 2027 at $1.72. We have an overall positive view on REI as it has pivoted to a pure-play necessity retail REIT after exiting all residential assets, but believe it already trades at a premium that reflects this transition. REI has near-record occupancy and strong re-leasing spreads over 15%, but is unable to grow NOI faster than 3.5% in the near term due to accelerating interest expense growth related to refinancing near-term obligations from low rates through 2027. REI's grocery-anchor focus (85% of centers, targeting 90%) and concentration in Canada's high-demographic major markets (277K population, $155K income within 5km) should provide strong cash flow that enables management to further pay down debt (currently at 8.6x net debt to adjusted EBITDA).
$REI.UN
Asia
Salubris Pharma's 2025 Profit Rises 8%, Revenue Climbs 9%; Shares Down 3%
Shenzhen Salubris Pharmaceuticals' (SHE:002294) net profit attributable to shareholders in 2025 rose 8.3% to 651.5 million yuan from 601.6 million yuan a year earlier, according to a Shenzhen bourse filing on Tuesday.Earnings per share climbed 7.4% year on year to 0.58 yuan from 0.54 yuan.Operating revenue increased 8.5% to 4.35 billion yuan from 4.01 billion yuan in the prior year.The pharmaceutical company's shares fell by over 3% during the midday trade.
$SHE:002294
Asia
Kingfa Sci & Tech 2025 Profit Up 39%, Revenue Rises 8%
Kingfa Sci & Tech (SHA:600143) posted 2025 attributable net profit of 1.15 billion yuan, up 39% from 824.6 million yuan the previous year.Earnings per share rose to 0.4459 yuan from 0.3120 yuan, according to a Tuesday filing with the Shanghai bourse.Operating revenue rose 8.1% year over year to 65.4 billion yuan from 60.5 billion yuan.In the fourth quarter of 2025, operating revenue from modified plastic products stood at 10.2 billion yuan, according to a separate filing. Operating revenue from green petrochemical products stood at 3.37 billion yuan and from new material products was 1.30 billion yuan.Shares of the plastic products manufacturer were down 1% in recent trade.
$SHA:600143